Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Attention Deficit Disorder with Hyperactivity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| SPD465-304 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2006-11-07 |
2021-08-24 |
Patient Enrollment|Primary Endpoints|Treatments |
|
| SPD465-303 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2005-11-04 |
2021-06-11 |
Primary Endpoints |
|
| SPD465-301 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2005-06-14 |
2021-07-01 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/09/2024 |
PubMed |
Studying the context of psychoses to improve outcomes in Ethiopia (SCOPE): Protocol paper. |
|
05/01/2024 |
PubMed |
Screening of Astec CHIRALDEX G-PN and LIPODEX D gas chromatography columns for enantioseparation of amphetamine derivatives. |
|
04/25/2024 |
PubMed |
Psychostimulants and social behaviors. |
|
01/03/2023 |
News Article |
QSYMIA (Phentermine-Topiramate) Drug Insights and Market Forecasts to 2032 |